Zobrazeno 1 - 3
of 3
pro vyhledávání: '"RAMON VILLAVERDE GONZALEZ"'
Autor:
Eva Fernandez‐Diaz, Jose A. Perez‐Vicente, Ramon Villaverde‐Gonzalez, Leticia Berenguer‐Ruiz, Antonio Candeliere Merlicco, Maria Luisa Martinez‐Navarro, Julia Gracia Gil, Carlos M. Romero‐Sanchez, Arantxa Alfaro‐Saez, Inmaculada Diaz, Juana Gimenez‐Martinez, Maria Angeles Mendez‐Miralles, Jorge Millan‐Pascual, Javier Jimenez‐Pancho, Santiago Mola, Angel P. Sempere
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 8, Iss 2, Pp 385-394 (2021)
Abstract Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are limited. The aim of this study was to evaluate the preliminary saf
Externí odkaz:
https://doaj.org/article/36e53a30c73a4e0f8bca14d2d0533bc6
Autor:
RAMON VILLAVERDE GONZALEZ
Publikováno v:
Degenerative Neurological and Neuromuscular Disease
Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, and degenerative disease that is up to three times more frequent in young women. MS does not alter fertility and has no impact on fetal development, the course of pregnancy, or child
Autor:
José E. Meca-Lallana, José M. Prieto González, Ana B. Caminero Rodríguez, Javier Olascoaga Urtaza, Ana M. Alonso, Eduardo Durán Ferreras, Raúl Espinosa, Julio Dotor, Mercedes Romera, Adrián Ares Luque, Domingo Pérez Ruiz, Carmen Calles, Miguel A. Hernández, Miguel Hervás García, Amelia Mendoza Rodríguez, Yasmina Berdei Montero, Nieves Téllez, Nicolás Herrera Varó, Javier Sotoca, Silvia Presas-Rodríguez, Luis A. Querol Gutierrez, Mariona Hervás Pujol, Jordi Batlle Nadal, Gisela Martín Ozaeta, Laura Gubieras Lillo, Sergio Martínez Yélamos, Lluís Ramió-Torrentà, Javier Mallada Frechin, Antonio Belenguer Benavides, Francisco Gascón-Giménez, Bonaventura Casanova, Lamberto Landete Pascual, Leticia Berenguer, Laura Navarro, Montserrat Gómez Gutierrez, Carmen Durán, Ana Rodríguez Regal, Elena Álvarez, Daniel A. García-Estévez, Ana M. López Real, Miguel A. Llaneza González, María E. Marzo Sola, José L. Sánchez-Menoyo, Agustín Oterino, Ramón Villaverde González, Tamara Castillo-Triviño, Amaya Álvarez de Arcaya, Cristina Llarena
Publikováno v:
Neurology and Therapy, Vol 12, Iss 6, Pp 2177-2193 (2023)
Abstract Introduction Teriflunomide is a once-daily oral immunomodulator approved for relapsing forms of multiple sclerosis (MS) or relapsing–remitting multiple sclerosis (RRMS; depending on the local label), based on extensive evidence from clinic
Externí odkaz:
https://doaj.org/article/0d5e12714aa14ddbb6e6eadf49cbbed1